BerGenBio
Vær den første som følger denne virksomhed
BerGenBio is a Norwegian oncology company. The company conducts research and development of inhibitory drugs for the treatment of aggressive cancers. The company has developed a number of products whose composition intends to block the protein AXL, a protein positively related to the spread of cancer cells. The company was founded in 2007 and is headquartered in Bergen.
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
Oslo Børs
BGBIO
Daglig lav / høj pris
-
Markedsværdi
-
Aktieomsætning
-
Volumen
-
Finanskalender
Generalforsamling
23.05.2024
Delårsrapport
29.05.2024
Delårsrapport
21.08.2024
Delårsrapport
13.11.2024
Årsrapport
19.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Meteva AS | 26,2 % | 26,2 % |
Investinor Direkte AS | 4,1 % | 4,1 % |
Premium
This content is for our Premium customers only.
ViserAlle indholdstyper
BerGenBio ASA: Exercise price in the last exercise period for warrants issued in connection with rights issue
BGBIO: BerGenBio Announces Initiation of Phase 2a in First Line Non-Small Lung Cancer Patients with a STK11 mutation
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools